Search

everythinglearnresearchcommunity

for

Search:↓

Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.

Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.

Microneedling with PRP is a safe and effective way to treat chronic alopecia areata, improving hair regrowth with minimal side effects.

Baricitinib is effective and safe for treating severe alopecia areata.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.

Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.